Amylyx Pharmaceuticals, Inc./$AMLX
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Amylyx Pharmaceuticals, Inc.
Amylyx Pharmaceuticals Inc is a clinical-stage pharmaceutical company working on developing a novel therapeutic for amyotrophic lateral sclerosis and other neurodegenerative diseases. It has one operating segment which is the business of researching and developing therapeutics for neurodegenerative disorder and endocrine conditions.
Ticker
$AMLX
Sector
Trading on
Industry
Pharmaceuticals
Headquarters
Employees
123
ISIN
US03237H1014
Website
AMLX Metrics
BasicAdvanced
$484M
-
-$3.02
-0.60
-
Price and volume
Market cap
$484M
Beta
-0.6
52-week high
$5.55
52-week low
$2.60
Average daily volume
1M
Financial strength
Current ratio
12.054
Quick ratio
11.397
Long term debt to equity
0.162
Total debt to equity
0.686
Management effectiveness
Return on assets (TTM)
-40.72%
Return on equity (TTM)
-83.24%
Valuation
Price to revenue (TTM)
-309.949
Price to book
2.4
Price to tangible book (TTM)
2.4
Price to free cash flow (TTM)
-1.62
Growth
Revenue change (TTM)
-100.32%
Earnings per share change (TTM)
185.96%
3-year revenue growth (CAGR)
64.64%
3-year earnings per share growth (CAGR)
-23.63%
AMLX News
AllArticlesVideos
Bronstein, Gewirtz & Grossman, LLC Is Investigating Amylyx Pharmaceuticals, Inc. (AMLX) And Encourages Investors to Connect
Accesswire·2 days ago
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Amylyx Pharmaceuticals, Inc. (AMLX) and Encourages Stockholders to Learn More About the Investigation
Accesswire·4 days ago
Bronstein, Gewirtz & Grossman, LLC Encourages Amylyx Pharmaceuticals, Inc. (AMLX) Investors to Inquire about Securities Investigation
Accesswire·1 week ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Amylyx Pharmaceuticals, Inc. stock?
Amylyx Pharmaceuticals, Inc. (AMLX) has a market cap of $484M as of May 22, 2025.
What is the P/E ratio for Amylyx Pharmaceuticals, Inc. stock?
The price to earnings (P/E) ratio for Amylyx Pharmaceuticals, Inc. (AMLX) stock is 0 as of May 22, 2025.
Does Amylyx Pharmaceuticals, Inc. stock pay dividends?
No, Amylyx Pharmaceuticals, Inc. (AMLX) stock does not pay dividends to its shareholders as of May 22, 2025.
When is the next Amylyx Pharmaceuticals, Inc. dividend payment date?
Amylyx Pharmaceuticals, Inc. (AMLX) stock does not pay dividends to its shareholders.
What is the beta indicator for Amylyx Pharmaceuticals, Inc.?
Amylyx Pharmaceuticals, Inc. (AMLX) has a beta rating of -0.6. This means that it has an inverse relation to market volatility.